Hypertrophic Cardiomyopathy Therapeutics
1. Camzyos patent expiration
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(8 years from now) | |
| USRE50050 | BRISTOL | Pyrimidinedione compounds |
Apr, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-297) | Jun 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2027 |
| Orphan Drug Exclusivity(ODE-398) | Apr 28, 2029 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: 28 April, 2026
Market Authorisation Date: 28 April, 2022
Dosage: CAPSULE
More Information on Dosage
CAMZYOS family patents
